Risk Factors for Acquiring Multidrug Resistant Microorganisms (MDROs) in Hospital Settings: A Retrospective Study in a Reference Center

Abstract

Multidrug-resistant microrganisms (MDROs) infections are a major challenge in hospitals. MDROs affect developed and developing countries and even intensive care and non-intensive care units. In this context, we conducted a study which aims to identify the factors leading to the acquisition of MDROs in a non-intensive care unit. Our study was a retrospective and analytical study. The frequency of diabetes was 64%. The factors leading to the acquisition of MDROs were: invasive medical care (P < 0.001); the presence of MDROs of a urinary catheter and nosocomial infections increased the risk of MDROs infection by six and nine times, respectively (OR 6.2 [95% CI: 2.1 - 17.9] and P < 0.001; OR 9.1 [95% CI: 3.2 - 25.2] and P < 0.001). MDROs are still common in patients with diabetes; infection prevention and control measures and antimicrobial stewardship programmes need to be implemented to better address the problem.

Share and Cite:

Andriananja, V., Botofotsy, E., Mandrosovololona, V., Randremasinjara, L., Randria, M.J.D. and Andrianasolo, R.L. (2026) Risk Factors for Acquiring Multidrug Resistant Microorganisms (MDROs) in Hospital Settings: A Retrospective Study in a Reference Center. Open Access Library Journal, 13, 1-11. doi: 10.4236/oalib.1113454.

1. Introduction

Multidrug resistant microrganism (MDROs) are defined as acquired non-susceptibility to an agent belonging to at least three categories of antimicrobial [1]. The emergence of antibiotic-resistant bacteria is a major public health concern. The World Health Organisation (WHO) has identified antibiotic resistance as one of the three most important threats to public health in the 21st century [2]. In Western sub-Saharan Africa, mortality linked to antimicrobial resistance is 27.3 deaths per 100,000 people. If no action is taken, this figure could rise to 10 million a year by 2050, exceeding the number of cancer-related deaths [3]. In Madagascar, in the intensive care and surgical wards of two hospitals in the city, Randrianirina et al. found ESBL strains in more than 30% of the bacteria isolated from various bacteriological samples taken from the patients included [4]. In the community, Herindrainy et al. reported faecal carriage of Gram-negative bacilli-ESBL in 10% of non-hospitalized patients (hospitalized, please change hospitalised in hospitalized, and hospitalisation in hospitalization) [5]. National data were limited on MDROs because the country had restricted surveillance capabilities, several local studies and public health initiatives show that multidrug-resistant microorganisms are actively circulating in various clinical and community settings.

It is in this context that our study will be carried out in a non-intensive care patient ward to better define the extent of the problem. The main objective is to identify the risk factors for the acquisition of multidrug resistant microrganism (MDROs) in a hospital environment in a non-intensive care patient ward.

2. Method

This study was carried out in the Endocrinology and Metabolism Department of the University Hospital in the city of Madagascar. The department specialises in the treatment of endocrine, metabolic and infectious diseases. The Endocrinology and Metabolism Department has 34 beds divided into 08 rooms, including isolation rooms. Our study was spread over a period of 4 years, from 01 January 2020 to 31 December 2023. All patients hospitalized in the Department of Metabolic and Endocrine Diseases from 2020 to 2023 with a documented microbiological diagnosis. Exclusion criteria were patients with microbiological documentation of: a fungal infection or a result suggesting contamination of the sample (e.g. mixed flora). Mycobacteria and other bacteria most commonly associated with community-acquired infections such as Streptococcus pneumoniae, Salmonella spp, Shigella spp and Neisseria gonorrhoeae were excluded.

We defined variables such as:

Sociodemographic parameters were sex (male or female), age group (in years), occupation, smoking, alcoholism, history of hospitalisation in the last 6 months.

Clinical parameters were reason for admission, comorbidities: diabetes (random blood glucose ≥ 2 g/dl) and/or hypertension (BP > 140/90 mmHg), chronic respiratory disease, chronic kidney disease, recent antibiotic use (within 3 months prior to hospitalisation), presence of invasive devices (urinary catheter, central venous catheter, mechanical ventilation), complications secondary to MDR infections (severe sepsis or septic shock), site of infection: urinary tract infection, bacteraemia, skin and soft tissue infection, catheter-associated bacteraemia, length of hospital stay.

Multidrug resistant microorganisms (MDROs): pathogenic strains that are resistant to ≥1 molecule of three or more TYPES of commonly susceptible antimicrobials drugs used in clinical practice at the same time [6].

Biological parameters during infection: CBC, CRP, ESR, serum creatinine, urea-microbiological parameters were type of bacteriological sample, microbiological results, antibiotic resistance profile. According to the literature, we define multi-resistant bacteria as Gram-positive and Gram-negative bacteria “resistant to at least three classes of antimicrobial agents”.

Microbiological procedures for identification included microscopic analysis, culture on selective media, and antibiogram according to French recommendations.

Microbiological methods:

Clinical specimens (urine, blood, pus, and other relevant samples) were processed according to standard microbiological procedures. Urine samples were cultured on Cystine-Lactose-Electrolyte-Deficient (CLED) agar and MacConkey agar, while pus and other non-sterile samples were cultured on Blood agar and MacConkey agar. Blood samples were inoculated into blood culture bottles and incubated using standard automated/manual blood culture systems; positive bottles were subcultured on Blood agar and MacConkey agar.

Bacterial identification was performed using conventional biochemical tests, and when available, automated identification systems. Antibiotic susceptibility testing was carried out using disk diffusion method, and results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. Multidrug-resistant organisms (MDROs) were defined as isolates resistant to at least one agent in three or more antimicrobial classes.

- Data collection: Data were collected on an individual record, recorded and analysed using Epi Info 7.5.2 software.

- Statistical analysis: Risk factors for acquiring MDROs infection were investigated by univariate analysis using the following statistical tests: odds ratio (OR) and 95% confidence interval (CI), chi-squared, Fisher’s exact test and Student’s t-test. Variables with a P-value ≤ 0.05 were considered significant.

3. Results

During the study period from 1 January 2020 to 31 December 2023, we recorded 65 cases of MDROs infection from a total of 101 positive specimens, giving a prevalence of 64.4%. The median age was 60 years (IQR: 50 - 67 years). Half of the patients (50.6%) were older than 60 years, the majority of whom were women (38) (59%) and men (27) (41%) (Table 1). Hypertension (37) (56.9%) and diabetes (62) (95.4%) were the most common comorbidities (Table 1). 23 (35.4%) patients had received antibiotics in the previous three months (Table 1). The use of medical devices was observed in 35 (53.8%) patients (Table 1). The site of infection was mainly urinary 30 (50%), Enterobacteriaceae 46 (70.8%) were the most common BMR (Table 1). The median length of hospital stay was 14 days, with an interquartile range (IQR) of 10 to 21 days. Of the patients, 31 (47.7%) have a hospital stay longer than 14 days.

Table 1. Patients’ characteristics.

Patient characteristics

n (%)

Comorbidities

Strokes

6 (9.2%)

Diabetes

62 (95.4%)

Chronic Alcoholism

11 (16.9%)

HIV

1 (1.5%)

High blood pressure

37 (56.9%)

Chronic kidney Diseases

8 (12.3%)

Chronic respiratory diseases

5 (7.7%)

Smoking

12 (18.5%)

Admission

Change in general condition

10 (15.4%)

Seizure

4 (6.1%)

Dyspnea

7 (10.8%)

Fever

11 (16.9%)

Wound

17 (26.2%)

Impaired of consciousness

9 (13.8%)

Others

5 (7.7%)

History of hospitalization in the last six months

Yes

28 (43.1%)

No

37 (56.9%)

Use of antibiotics in the last 3 months

Yes

23 (35.4%)

No

42 (64.6%)

Use of medical devices

Yes

35 (53.8%)

No

30 (46.2%)

Medical devices

Parenteral nutrition

7 (20%)

Central nervous catheter

3 (8.6%)

Chest drain

1 (2.9%)

Nasogastrique Tube

7 (20%)

Urinary catheter

33 (94.3%)

Site of infection

Blood stream infection

10 (6%)

Skin and soft tissues osteitis

22 (36.7%)

Surgical site infection

3 (3.3%)

Urinary tract infection

30 (50%)

Type of infection

Acquired in community

27 (41.5%)

Acquired in hospital

38 (58.5%)

Complications

Non complicated

18 (28.1%)

Severe respiratory syndrome

26 (40.6%)

Septic shock

20 (31.3%)

Biological results (médiane, IQR)

ESR, G/L

3.99 (3.42 - 4.59)

Haemoglobin, g/dl

11.2 (9.6 - 12.5)

Hematocrit, %

31.9 (27.6 - 35.7)

WBC, G/L

14.47 (10.4 - 22.2)

PNN, G/L

11.3 (8.1 - 19.7)

Lymphocyte, G/L

1.7 (1.2 - 2.67)

Plaquette, G/L

318 (227 - 442)

CRP, mg/dl

75.7 (47 - 106)

Creatininemia, µmol/L

152 (103 - 221)

Urea, mmol/l

11.7 (7.2 - 18.9)

HbA1C, %

9.7 (7.6 - 12)

ASAT, UI

30 (23 - 45)

ALAT, UI

23 (17 - 43)

Na2+, mmol/l

136 (130 - 140)

K2+, mmol/l

4 (3.2 - 4.7)

Cl−, mmol/l

98.5 (94 - 105)

Type of samples

Urine culture

31 (47.7%)

Pus

28 (43.1%)

Blood culture

6 (9.2%)

Isolated Microorganisms

Enterobacteria spp

46 (70.8%)

Enterococcus spp

3 (4.6%)

Pseudomonas spp

5 (7.7%)

Staphylococcus spp

11 (16.9%)

Enterobacteria spp isolated

Acinetobacter spp

2 (4.4%)

E. coli

25 (54.4%)

Enterobacter spp

2 (4.4%)

Citrobacter spp

1 (2.2%)

Klebsiella spp

10 (21.7%)

Serratia spp

1 (2.2%)

Shigella spp

1 (2.2%)

Proteus spp

3 (6.5%)

Antibiotics used

AMOXICILLIN-acide clavulanique

3 (3.8%)

Ceftriaxone

5 (6.3%)

Imipenem

33 (41.8%)

Meropenem

1 (1.3%)

AMIKACIN

25 (31.6%)

GENTAMICIN

1 (1.3%)

CIPROFLOXACIN

4 (5.1%)

Levofloxacin

1 (1.3%)

Vancomycin

13 (16.5%)

CLINDAMYCIN

1 (1.3%)

Chloramphenicol

1 (1.3%)

Availability of prescribed antibiotics

Administered

36 (55.3%)

Non administered

29 (44.7%)

Duration of hospital stay (médiane, IQR)

14 (10 - 21)

Outcome of patients

Alive

51 (78.5%)

Deaths

14 (21.5%)

Here is the profile of resistant Enterobacteriaceae, 37 (80.4%) were ESBL resistant to Third cephalosporin generation, 39 (84%) resistant to CIPROFLOXACIN and 5 (10%) showed resistance to IMIPENEM (Table 2).

In univariate analysis, a significant association was found between the presence of invasive medical care and an increased risk of developing an MDR infection (P < 0.001). The presence of a urinary catheter and nosocomial infections increased the risk of MDR infection by a factor of six and nine, respectively (OR 6.2 [95% CI: 2.1 - 17.9] and P < 0.001; OR 9.1 [95% CI: 3.2 - 25.2] and P < 0.001) (Table 3).

Table 2. Resistance profile according to antibiotics tested.

Antibiotics

Effective

Résistance n (%)

Amoxiciline

44

95.7%

Amoxicilline acide clavulanique

40

87.0%

Ceftriaxone

37

80.4%

Cefixime

37

80.4%

Ceftazidime

37

80.4%

Imipenem

5

10.9%

Gentamicine

38

83.0%

Amikacine

2

4.4%

Acide nalidixique

27

58.7%

Ofloxacine

29

63%

Ciprofloxacine

39

84.7%

Chloramphenicol

11

25.6%

Cotrimoxazole

42

91.3%

Table 3. Risk factors for acquiring MDR infections in univariate analysis.

Risk factors

Non MDR

MDR

OR

IC 95%

P

Gender:

Man

12

27

1.36

0.5 - 3.2

0.6

Women

23

38

Age:

<60 years

21

32

1.4

0.6 - 3.2

0.3

≥60 years

14

33

Comorbidities:

Yes

35

62

1.5

1.3 - 1.8

0.2

No

0

3

Diabetes:

Yes

Not defined

Not defined

-

-

-

No

Chronic Kidney disease:

Yes

4

8

1.08

0.3 - 3.9

0.8

No

37

57

Chronic respiratory disease:

Oui

3

5

0.8

0.2 - 3.9

0.8

Non

32

60

Previous hospitalization:

Oui

9

28

2.1

0.8 - 5.3

0.08

Non

26

37

Previous antibiotic use:

Yes

5

23

3.3

1.1 - 9.6

0.02

No

30

42

Medical devices:

Yes

5

35

6.7

2.3 - 19.7

˂0.005

No

28

29

Urinary catheter:

Yes

5

33

6.2

2.1 - 17.9

˂0.005

No

30

32

Nasogastrique tube:

Yes

0

7

-

-

-

No

35

58

Central venous catheter:

Yes

0

3

-

-

-

No

35

62

Parenteral nutrition:

Yes

1

3

1.6

0.1 - 16.4

0.5

No

34

62

Hospital acquired infection:

Yes

6

43

9.12

3.2 - 25.2

˂0.005

No

28

22

Length of stay > 7 days:

Yes

34

60

2.8

0.3 - 25.1

0.3

No

1

5

4. Discussion

This study revealed a high frequency of 64.4% of multidrug resistant microorganisms (MDROs) infections in a non-intensive care unit, particularly in endocrinology. According to the literature, the high percentage of MDROs is mainly found in intensive care units, estimated at 66% [7]. The fact that our study was carried out in diabetic patients explains the high frequency of MDROs. This result is consistent with a study carried out in an African infectious diseases department, which showed that among the 111 MDROs infections hospitalized, the prevalence of diabetics was 59.4% (n = 66, CI95%: 0.50 - 0.68), with an average age of 64.3 years and a sex ratio of 0.44 [8]. In contrast, developed countries have much lower prevalences, between 20% and 30% [9] [10]. This disparity could be explained by the lack of access to drinking water and WASH services, as well as by the over-consumption of antibiotics in developing countries. Our study population is also characterized by an over-representation of elderly people (≥60 years) and 95% diabetic patients (diabetes, hypertension), who are two groups at increased risk of colonization and infection by BMR due to immunosenescence, metabolic comorbidities and repeated hospitalizations and antibiotic use. In the face of these co-morbidities, the use of invasive devices (central venous catheters, urinary catheters, mechanical ventilation, etc.) is necessary. All conditions necessary for the acquisition of MDROs were fully met.

After an analytical study, we identified the risk factors for MDROs acquisition: invasive medical care OR = 6.7 (P < 0.005), the presence of a urinary catheter presents an even higher risk, with an OR = 17.9 (P < 0.005), nosocomial or healthcare-associated infections appear to be a major risk factor for BMR acquisition, with an OR = 9.12 (P < 0.005), demonstrating a highly significant association. These results have been confirmed by previous studies [11] [12]. Invasive medical devices create a direct point of entry for pathogens, bypassing natural defences such as skin or mucous membranes and the biofilm that forms [11].

Among the multidrug-resistant organisms (MDROs), Enterobacteriaceae accounted for 80.4% of isolates in our study, a proportion markedly higher than that reported in some European studies (14%). A comparable prevalence has been reported in studies conducted in Cameroon, where Enterobacteriaceae were identified in nearly 100% of cases [13]-[15]. This high prevalence observed in our setting, compared with developed countries, may be explained by the extensive use of third-generation cephalosporins, which promotes the selection of β-lactamase-producing strains. Resistance to IMIPENEM (10.9%) is particularly concerning, as this antibiotic is often considered a last-resort treatment. Extended-spectrum β-lactamase (ESBL)-producing organisms were the predominant pathogens in both intensive care and non-intensive care units. Furthermore, this study reflects the reality in low- and middle-income countries, which is not directly comparable to the European context. However, it highlights the disproportionate burden of multidrug-resistant organisms (MDROs) in Africa and underscores the suboptimal implementation of antimicrobial stewardship programs in these settings, as well as the urgent need to strengthen infection prevention and control strategies and rational antibiotic use.

This study has several limitations, including its single center nature, methodological constraints and a relatively small sample size, which did not allow for multivariate analysis. In addition, the identified risk factors did not take prior antibiotic consumption into account. Despite of its limitations, it highlights the substantial burden of multidrug-resistant organisms (MDROs), which represent a significant public health threat in Madagascar. This issue affects both intensive care and non-intensive care units. Mortality remains substantial (21.5%) despite very limited medical resources. Consequently, infection prevention and control (IPC) measures particularly patient isolation, environmental cleaning, and hand hygiene must be strengthened to control infections and prevent their spread. Regular training of healthcare workers is essential to ensure appropriate patient care. In addition, the implementation of a rational antibiotic use program, supported by national guidelines and aligned with the WHO AWaRe classification, is crucial to prevent antibiotic misuse.

5. Conclusion

Diabetic patients are at particularly high risk of infection with multidrug-resistant organisms (MDROs), due to immune dysfunction, frequent healthcare exposure and medical devices use. Strengthening infection prevention and control (IPC) measures, including strict hand hygiene, appropriate patient isolation, and environmental cleaning, is essential to reduce transmission within healthcare settings. In parallel, robust antimicrobial stewardship programs are crucial to optimize antibiotic prescribing, limit unnecessary exposure to broad-spectrum agents, and ultimately improve patient outcomes by preventing the emergence and spread of MDROs.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Centers for Disease Control and Prevention (CDC) About Antimicrobial Resistance.
[2] WHO (2022) Antimicrobial Resistance.
https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
[3] Murray, C.J.L., Ikuta, K.S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., et al. (2022) Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. The Lancet, 399, 629-655.[CrossRef] [PubMed]
[4] Randrianirina, F., Vaillant, L., Ramarokoto, C.E., Rakotoarijaona, A., Andriamanarivo, M.L., Razafimahandry, H.C., et al. (2010) Antimicrobial Resistance in Pathogens Causing Nosocomial Infections in Surgery and Intensive Care Units of Two Hospitals in Antananarivo, Madagascar. The Journal of Infection in Developing Countries, 4, 74-82.[CrossRef] [PubMed]
[5] Herindrainy, P., Randrianirina, F., Ratovoson, R., Ratsima Hariniana, E., Buisson, Y., Genel, N., et al. (2011) Rectal Carriage of Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacilli in Community Settings in Madagascar. PLOS ONE, 6, e22738.[CrossRef] [PubMed]
[6] Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. (2012) Multidrug-Resistant, Extensively Drug-Resistant and Pandrug-Resistant Bacteria: An International Expert Proposal for Interim Standard Definitions for Acquired Resistance. Clinical Microbiology and Infection, 18, 268-281.[CrossRef] [PubMed]
[7] El-Mekes, A., Zahlane, K., Ait said, L., Tadlaoui Ouafi, A. and Barakate, M. (2020) The Clinical and Epidemiological Risk Factors of Infections Due to Multi-Drug Resistant Bacteria in an Adult Intensive Care Unit of University Hospital Center in Marrakesh-morocco. Journal of Infection and Public Health, 13, 637-643.[CrossRef] [PubMed]
[8] Saad, L., Kooli, I., Kadri, Y., Abdejlil, M., Marrakchi, W., Aouam, A., et al. (2020) Les bactéries multirésistantes (BMR) chez le diabétique: Etude épidémio-clinique. Annales dEndocrinologie, 81, 408-456.[CrossRef]
[9] European Centre for Disease Prevention and Control and World Health Organization (2023) Antimicrobialresistance Surveillance in Europe 2023: 2021 Data. Publications Office of the EU.
[10] Cassini, A., Högberg, L.D., Plachouras, D., Quattrocchi, A., et al. (2019) Attributable Deaths and Disability-Adjusted Life-Years Caused by Infections with Antibiotic-Resistant Bacteria in the EU and the European Economic Area in 2015: A Population-Level Modelling Analysis. The Lancet Infectious Diseases, 19, 56-66.
[11] Diao, H., Lu, G., Zhang, Y., Wang, Z., Liu, X., Ma, Q., et al. (2024) Risk Factors for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter Baumannii Infection of Patients Admitted in Intensive Care Unit: A Systematic Review and Meta-Analysis. Journal of Hospital Infection, 149, 77-87.[CrossRef] [PubMed]
[12] Rodríguez-Baño, J., Picón, E., Gijón, P., Hernández, J.R., Ruíz, M., Peña, C., et al. (2010) Community-Onset Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: Risk Factors and Prognosis. Clinical Infectious Diseases, 50, 40-48.[CrossRef] [PubMed]
[13] Njall, C., Adiogo, D., Bita, A., Ateba, N., Sume, G., Kollo, B., et al. (2013) Écologie bactérienne de l’infection nosocomiale au service de réanimation de l’hôpital Laquintinie de Douala, Cameroun. Pan African Medical Journal, 14, Article 140.
[14] Guillard, F., Merens, A., Dortet, L., Janvier, F., Lebrun, C., Yin, N., et al. (2019) Évaluation de la prévalence de la résistance aux antibiotiques chez les entérobactéries isolées de prélèvements urinaires dans les services d’urgence de France. Médecine et Maladies Infectieuses, 49, S111-S112.[CrossRef]
[15] Lonchel, C.M., Meex, C., Gangoué-Piéboji, J., Boreux, R., et al. (2012) Proportion of Extended-Spectrum Ss-Lactamase-Producing Enterobacteriaceae in Community Setting in Ngaoundere, Cameroon. BMC Infectious Diseases, 12, Article No. 53.[CrossRef] [PubMed]

Copyright © 2026 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.